RT Journal Article
T1 Long non-coding RNA signatures in the Ileum and colon of Crohn´s disease patients and efect of anti-TNF-α treatment on their modulation
A1 Baldan-Martin, Montse
A1 Rubín de Célix, Cristina
A1 Orejudo, Macarena
A1 Ortega Moreno, Lorena
A1 Fernández-Tomé, Samuel
A1 Soleto, Irene
A1 Ramirez, Cristina
A1 Arroyo, Ricardo
A1 Fernández, Paloma
A1 Santander, Cecilio
A1 Moreno-Monteagudo, José
A1 Casanova, María
A1 Casals, Fernando
A1 Casabona, Sergio
A1 Becerro, Irene
A1 Lozano, Juan
A1 Aransay, Ana
A1 Chaparro, María
A1 Gisbert, Javier
AB Biological therapies only benefit one-third of patients with Crohn’s disease (CD). For this reason, a deeper understanding of the mechanisms by which biologics elicit their effect on intestinal mucosa is needed. Increasing evidence points toward the involvement of long noncoding RNAs (lncRNAs) in the pathogenesis of CD, although their role remains poorly studied. We aimed to characterize lncRNA profiles in the ileum and colon from CD patients and evaluate the effect of anti-TNF-α treatment on their transcription. Terminal ileum and left colon samples from 30 patients (active CD = 10, quiescent CD = 10, and healthy controls (HCs) = 10) were collected for RNA-seq. The patients were classified according to endoscopic activity. Furthermore, biopsies were cultured with infliximab, and their transcriptome was determined by Illumina gene expression array. A total of 678 differentially expressed lncRNAs between the terminal ileum and left colon were identified in HCs, 438 in patients with quiescent CD, and 468 in patients with active CD. Additionally, we identified three new lncRNAs in the ileum associated with CD activity. No differences were observed when comparing the effect of infliximab according to intestinal location, presence of disease (CD vs. HC), and activity (active vs. quiescent). The expression profiles of lncRNAs are associated with the location of intestinal tissue, being very different in the ileum and colon. The presence of CD and disease activity are associated with the differential expression of lncRNAs. No modulatory effect of infliximab has been observed in the lncRNA transcriptome.
SN 1422-0067
YR 2023
FD 2023
LK https://hdl.handle.net/20.500.14352/109518
UL https://hdl.handle.net/20.500.14352/109518
LA eng
NO Int. J. Mol. Sci. 2023, 24(21), 15691; https://doi.org/10.3390/ijms242115691
DS Docta Complutense
RD 4 abr 2025